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Background and Objectives
The optimal post-remission treatment for elderly patients with acute myeloid leukemia
(AML) is presently unknown. Recent studies have reported the feasibility of autolo-
gous peripheral blood stem cell transplantation (PBSCT) in this population. We eval-
uate the outcome of this post-remission approach after complete remission (CR) and
consolidation in elderly patients included in the EORTC – GIMEMA AML – 13 trial.
Design and Methods
PBSCT after induction and consolidation chemotherapy was evaluated in patients
aged 61 to 70 years old with a WHO performance status 0-1. The induction therapy
was mitoxantrone, etoposide and cytarabine (MICE) with or without granulocyte
colony-stimulating factor (G-CSF) during and/or after chemotherapy. The consolidation
therapy consisted of non-infusional or infusional idarubicin, etposide and cytarabine
(mini-ICE).  
Results
Sixty-one patients were scheduled for stem cell harvest by leukapheresis after s.c.
recombinant human G-CSF administration initiated after hematopoietic recovery from
consolidation. Stem cells were effectively harvested from 54 patients. A median of
two aphereses (range, 1–5) were performed, resulting in a median collection of
11.7×108 nucleated cells/kg (range, 2.4–99.8) containing 40.2×104 CFU-GM/kg
(range, 0–786.8), and 5×106 CD34+ cells/kg (range, 0.1–99.8). For the whole group
of 61 patients, the median disease-free survival (DFS) was 1.0 years and the 3-year
DFS rate was 21%, while the median overall survival (OS) was 1.4 years and the 3-
year OS rate was 32%. A total of 26 patients could not be autografed due to inade-
quate/no harvest (21 patients), early relapse (3 patients), or treatment refusal (2
patients). Autologous transplantation was performed in 35 patients following condi-
tioning with the BAVC regimen. The median time for granulocyte recovery >0.5×109/L
was 24 days and for platelets >20×109/L was 23 days following transplantation. After
a median follow-up of 5.0 years from transplantation, the median DFS and OS were
1.1 and 1.6 years, respectively, and the 3-year rates were 28% and 39%, respective-
ly. Eight autografted patients were still in continuous complete remission, 22 patients
had relapsed and five had died in CR.
Interpretation and Conclusions
Intensification of remission treatment including autologous PBSCT was feasible in
about half of harvested patients aged 61 to 70 years old, and did not improve the
general outcome. This shows the limitations of autologous PBSCT and other inten-
sive treatment modalities in elderly AML patients.
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ABSTRACT
Autologous stem cell transplantation after complete remission
and first consolidation in acute myeloid leukemia patients aged
61-70 years: results of the prospective EORTC–GIMEMA AML–13
study
Xavier Thomas, Stefan Suciu, Bernard Rio, Giuseppe Leone, Giorgio Broccia, George Fillet,
Ulrich Jehn, Walter Feremans, Giovanna Meloni, Marco Vignetti, Theo de Witte, Sergio Amadori
DECISION MAKING AND PROBLEM SOLVING
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The incidence of acute myeloid leukemia (AML)increases with age and more than 50% of AMLpatients are over 60 years old. These patients have a
poor outcome with complete remission (CR) rates of about
50% and less than 20% achieve long-term remission com-
pared with 40% of patients less than 60 years old.1,2
Numerous factors may contribute to the inferior outcome
with intensive therapy in older patients. Older patients
more often have poor-risk leukemic characteristics, such as
unfavorable karyotypes, myelodysplastic features, or a
chemoresistant profile.3 Furthermore, older patients often
have more or more severe comorbid conditions than
younger patients and tolerate prolonged pancytopenia and
intensive therapy less well.4
The addition of etoposide to an anthracycline/cytara-
bine regimen during induction and consolidation has been
shown to prolong CR in young adults with newly diag-
nosed AML.5 There is general agreement that some sort of
post-remission treatment should be used after reaching
CR. Its intensity, however, is an open question particularly
in the elderly. Several trials have suggested that consolida-
tion of AML in first complete CR with high-dose cytara-
bine is not usually feasible and associated with more toxic
deaths and relapses in patients over 60 years old when
compared with younger patients.6,7 A myeloablative regi-
men followed by autologous stem cell transplantation
reduces the relapse rate in young adult AML patients.8-11
Furthermore, peripheral blood stem cell support has been
shown to be superior to bone marrow support in terms of
hematologic recovery, with less than 10% transplant-relat-
ed mortality.12-16 Several recent studies have reported the
feasibility of autologous peripheral blood stem cell trans-
plantation (PBSCT) in elderly AML patients,17-23 including
patients aged above 70 years.22 These observations allowed
us to propose administering one or more intensive consol-
idation therapy regimens to a larger number of patients at
increasing ages. 
We, therefore, studied the outcome of combining these
approaches in elderly patients with newly diagnosed
AML. The conditioning schedule for these elderly patients
needed to be myeloablative without causing excessive tox-
icity. We selected the BAVC conditioning schedule which
is remarkably well tolerated in old patients.17,24 The aim of
the present study was to confirm the feasibility of periph-
eral blood stem cell collection and the tolerance of the
BAVC conditioning regimen and to evaluate the outcome
of peripheral blood stem cell support after one or two
induction chemotherapy course and one standard dose
consolidation course in AML patients ≤70 years of age, reg-
istered in the EORTC-LG/GIMEMA trial (AML-13).
Design and Methods
Study design
The AML-13 trial was a randomized phase III study
carried out by the European Organization for Research
and Treatment of Cancer and Gruppo Italiano Malattie
Ematologiche dell’Adulto (EORTC/GIMEMA) leukemia
groups in 53 European centers. This prospective trial
was designed (Figure 1) for patients 61–80 years of age
with previously untreated de novo or secondary AML.
The final protocol was approved by the EORTC
Protocol Review Committee and by the Ethical
Committee of each participating center. Before inclu-
sion all patients had to sign informed consent which
was in accordance with the Helsinki protocol. 
The two first objectives of the study were: (i) to deter-
mine the efficacy and toxicity of adding granulocyte
colony-stimulating factor (G-CSF) to induction
chemotherapy; (ii) to assess the role of non-infusional
mini-ICE as consolidation relative to i.v. mini-ICE.
Detailed analyses of the induction therapy and consoli-
dation chemotherapy have been reported elsewhere.25,26
We report here the results of the last (optional) objective
of this trial, namely the feasibility of myeloablative
chemotherapy followed by autologous PBSCT as a sec-
ond consolidation course. At selected centers, complete
responders with a good performance status and an age
≤70 years were offered an intensified second consolida-
tion consisting of myeloablative chemotherapy fol-
lowed by re-infusion of autologous peripheral blood
stem cells collected after hematologic recovery follow-
ing the first consolidation course.1
Eligibility criteria
Patients aged more than 60 years and ≤80 years old,
with newly diagnosed de novo AML or AML secondary
to a preceding myelodysplastic syndrome (MDS) or to
toxic exposure were eligible for this trial, provided they
had a good performance status (grade 0, 1 or 2, WHO
scale) and no severe organ failure. Patients were eligible
for the high dose chemotherapy with peripheral blood
stem cell support as the second consolidation course if
they met the following criteria after the first consolida-
tion course: persistence of CR, absence of organ dam-
age, the absence of severe infection, WHO performance
status 0 or 1, age 61-70 years old at registration.
Figure 1. Design of AML-13 study.
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Criteria of evaluation
AML was diagnosed according to the French-
American-British (FAB) criteria27,28 and a central review
was done in all cases. Bone marrow was assessed for
response approximately 3 weeks after the end of
chemotherapy. The Cancer and Leukemia Group B
(CALGB) criteria were used to determine response to
treatment and relapse.29 The International System for
Cytogenetic Nomenclature (ISCN) was used for the
cytogenetic classification.30 The cytogenetic data were
reviewed centrally. Twenty analyzed metaphases were
required to include a patient in the group with a cytoge-
netically normal karyotype (NN group). Complex abnor-
malities were defined as a clone with at least four unre-
lated abnormalities. The patients with unknown, not
done, or unsuccessful cytogenetics were grouped togeth-
er as unknown. Abnormalities 16q(22) and t(8;21) were
considered favorable risk abnormalities, whether other
abnormalities were present or not. NN karyotypes or
those with –Y only were classified as intermediate risk.
Entire or partial deletions of chromosome 5 and/or 7, the
presence of complex abnormalities (more than three
abnormalities) or trisomy 8 were considered of unfavor-
able prognosis. Patients with other abnormalities were
pooled into a separate cytogenetic risk group (other).
Chemotherapy
The design of the trial is shown in Figure 1. Induction
chemotherapy included one or two courses of MICE
combining mitoxantrone 7 mg/m2/day i.v. on days 1, 3,
and 5, with etoposide 100 mg/m2/day i.v. on days 1 to 3
and cytarabine 100 mg/m2/day i.v. as a continuous infu-
sion, on days 1 to 7. Recombinant human G-CSF
(rHuG-CSF) (lenograstim, 150 µg/m2/day) was random-
ized to be given during and/or after chemotherapy. In
arm 1A, patients did not receive any rHuG-CSF, while
patients received it on days 1 through 7 in arm 1B, on
days 8 through 28 in arm 1C, and on days 1 through 28
in arm 1D. Patients in CR after one or two courses of
induction treatment were to receive two courses of con-
solidation, administered as early as possible following
hematologic recovery. Consolidation was randomized
between i.v. mini-ICE vs non-infusional mini-ICE.
Intravenous mini-ICE comprised idarubicin 8
mg/m2/day i.v. on days 1, 3, and 5, associated with
etoposide 100 mg/m2/day on days 1 to 3 and cytarabine
100 mg/m2/day i.v. as a continuous infusion, on days 1
to 5. Non-infusional mini-ICE consisted of idarubicin 20
mg/m2/day p.o. on days 1, 3, and 5, associated with
etoposide 100 mg/m2/day p.o., twice daily, on days 1 to
3 and cytarabine 50 mg/m2/day s.c., twice daily, on days
1 to 5. 
Stem cell transplantation
After receiving the first consolidation treatment,
patients (at 18 participating centers) aged less than 70
years with a performance status <2 were scheduled for
peripheral blood stem cell harvest. The harvest was per-
formed by aphereses, beginning after 3 to 5 days of sub-
cutaneous treatment with G-CSF (lenograstim) at a daily
dose of 150 µg/m2, initiated within 2 weeks after hema-
tologic recovery from the first consolidation course.
According to the protocol, the total blood stem cell har-
vest should contain a target dose of at least 2×106 CD34+
cells/kg. As a surrogate marker for the mobilizing capac-
ity after consolidation treatment, we adopted the highest
yield of a single apheresis cycle. The total number of
CD34+ cells harvested could not be used for this purpose
since this was influenced by the predefined target of
2x106 CD34+cells/kg. PBSCT was performed after a
BAVC conditioning regimen consisting of carmustine
(BCNU) 800 mg/m2 on day –6, amsacrine 150 mg/m2/day
on days –5, –4, and –3, etoposide 150 mg/m2/day on days
–5, –4, and –3, and cytarabine 300 mg/m2/day on days –5,
–4, and –3.
Supportive care
Supportive care during induction, consolidation and
autologous transplantation included the use of reverse
isolation or sterile room, prophylactic red blood cell and
platelet transfusions, antibacterial and antifungal gastroin-
testinal decontamination, and the empirical use of antibi-
otics if the patient became febrile.
Statistical analysis
Disease-free survival (DFS) was defined from the date
of CR to the date of relapse or death, or last contact with
patient in continuous CR. The time to relapse and time
to death in CR were calculated as the DFS, but the fol-
low-up of patients who died in CR and those who
relapsed were censored at that moment for these two
analyses. By definition, all patients who died in CR were
considered to have died from a treatment-related cause.
Overall survival (OS) was defined as the time from CR to
death or last contact with the patient. DFS and OS prob-
abilities were calculated using the Kaplan and Meier
product-limit estimate method. The standard errors of
the estimates were calculated according to Greenwood’s
method. The estimates of the incidence of relapse and of
death in CR, and their corresponding standard errors,
were obtained using the cumulative incidence method,
in which the risks of death in CR and of relapse were
considered as competing risks.31 Duration of recovery
was defined as the time from the start of stem cell trans-
plantation until granulocyte or platelet recovery; the fol-
low-ups of patients without recovery were censored at
day 120. The database was frozen on November 2003.
Autologous SCT in AML
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All computations were made using SAS 8.2 statistical
software (SAS Institute Inc., Cary, NC, USA).
Results
Feasibility of autologous SCT
From December 1995 to February 2001, a total of 757
patients (median age, 67 years; range, 61–80 years) were
registered in the AML-13 trial. Before starting the trial,
centers were asked to choose between the use of a sec-
ond mini-ICE consolidation course in all patients aged
61 to 70 years in good clinical condition (WHO per-
formance status 0 or 1), or to administer myeloablative
chemotherapy followed by autologous PBSCT.
Eighteen participating centers that chose the second
therapeutic option entered 445 AML patients, of whom
278 were aged less than 71 years. One hundred and
fifty-nine of these patients (57%) achieved a CR, of
whom 134 were randomized to the consolidation arm
(non-infusional or i.v. mini-ICE), and effectively
received the assigned consolidation course. Patients
with a WHO performance status 0 or 1 were then theo-
retically scheduled for stem cell harvest by leukaphere-
sis after 3-5 days of subcutaneous recombinant human
G-CSF initiated after hematopoietic recovery from con-
solidation. Out of 132 patients who were still in CR
after the first consolidation course, 113 had a perform-
ance status <2. Among those, 59 (47%) patients were
scheduled for stem cell harvest, whereas 54 were not.
Reasons for not planning stem cell harvest were early
relapse (15 patients), toxicity of the first consolidation
course (20 patients), patients’ refusal (6 patients), or mis-
cellaneous (13 patients). Stem cells were effectively har-
vested from 52 patients, of whom 38 had an adequate
harvest. Among these, five patients have not been trans-
planted due to an early relapse (3 patients) or refusal of
further treatment (2 patients). Autologous PBSCT was
performed in 33 patients following conditioning with
the BAVC regimen (Figure 2). Two patients with a per-
formance status of 2 also underwent stem cell harvest-
ing and received autologous PBSCT their at physicians’
decision. These two patients were included in the fol-
lowing calculations.
Peripheral blood stem cell collection
Overall 61 patients (median age, 65 years; range, 61 -
70 years) were scheduled for stem cell harvest. Their ini-
tial cytogenetics, FAB subtypes and main treament char-
acteristics are shown in Table 1. Thirty-three patients
received i.v. mini-ICE as the first consolidation course,
while 28 received non-infusional mini-ICE. The median
duration of lenograstim administration was 5 days
(range, 2 – 27 days). Stem cell harvest was performed in
a stable phase in all patients, except in one case in
whom G-CSF was started on day 6 of the consolidation
X. Thomas et al.
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Figure 2. Feasibility
of autologous trans-
plantation.
Table 1. Characteristics of patients scheduled for stem cell trans-
plantation.
Features Patients not autografted Autografted patients
(n=26) (n=35)
Age (years)
Median (range) 65 (60–70) 63 (60–69)*
Gender
Male 17 (65.3%) 16 (45.7%)
Female 9 (34.7%) 19 (54.3%)
FAB classification
M0 0 2 (5.7%)
M1 3 (11.5%) 5 (14.3%)
M2 9 (34.7%) 11 (31.4%)
M4 6 (23.1%) 5 (14.3%)
M5 6 (23.1%) 9 (25.7%)
M6 0 (0%) 1 (2.9%)
M7 1 (3.8%) 1 (2.9%)
Not determined 1 (3.8%) 1 (2.9%)
Cytogenetics
Cytogenetics available** 14 (53.8%) 19 (54.3%)
Favorable risk*** 0 2 (10.5%)
Intermediate risk***
Normal (NN) 6 (42.9%) 9 (47.3%)
–Y 2 (14.3%) 1 (5.2%)
Unfavorable risk***
+ 8 2 (14.3%) 1 (5.2%)
–5, –7, complex 4 (28.5%) 4 (21.0%)
Others 0 2 (10.5%)
First randomization
MICE – G-CSF (-/-) 4 (15.4%) 7 (20.0%)
MICE – G-CSF (+/-) 4 (15.4%) 6 (17.1%)
MICE – G-CSF (-/+) 7 (26.9%) 7 (20.0%)
MICE – G-CSF (+/+) 10 (38.5%) 13 (37.1%)
MICE (not randomized) 1 (3.8%) 2 (5.7%)
Second randomization
i.v. mini-ICE 11 (42.3%) 22 (62.9%)
non-infusional mini-ICE 15 (57.6%) 13 (37.1%)
* range; ** percentage determined on the entire cohort; ***percentages
determined on patients with available cytogenetics. 
Autologous SCT in AML
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course and harvest performed at the time of cell recov-
ery. In seven of these 61 patients, the number of CD34+
circulating cells remained below the threshold for start-
ing an apheresis in spite of administration of recombi-
nant human G-CSF administration. The median time
between the start of the first consolidation course and
the start of lenograstim was 45 days (range, 6–124
days). In the 54 patients in whom a harvest was per-
formed, a median of two aphereses (range, 1–5) were
performed, resulting in a median collection of 11.7×108
nucleated cells/kg (range, 2.4–99.8) containing 40.2×104
CFU-GM/kg (range, 0–786.8), and 5×106 CD34+ cells/kg
(range, 0.1–99.8). Based on the highest harvest of CD34+
cells obtained during a single apheresis, 12 patients
were considered to have a low CD34+ yield (<
1×106/kg), 27 patients an intermediate CD34+ yield
(1–6.9×106/kg), and 15 patients a high CD34+ yield
≥7×106/kg). The cumulative CD34+ yield was consid-
ered to be adequate for PBSCT in 40 patients. The medi-
an follow-up from the start of the first consolidation
course was 4.6 years. For the whole group of 61
patients, the median DFS was 1.0 years and the 3-year
DFS rate was 21% (95% CI: 11–31%) (Figure 3), while
the median OS was 1.5 years and the 3-year OS rate
was 32% (95% CI: 20–44%). The 3-year relapse inci-
dence was 69% (SE=6%), while the 3-year incidence of
death in CR was 10% (SE=4%). 
A total of 26 patients could not be autografed due to
inadequate/no harvest (21 patients), early relapse (3
patients), or treatment refusal (2 patients). Among them,
10 ten patients received a second course of consolida-
tion. At the time of analysis, three of the 26 patients not
autografted were still in continuous CR, 22 patients had
relapsed and 1 had died from toxicity while in CR. By
intent-to-treat analysis, the treatment outcome of
patients who had been scheduled for peripheral blood
stem cell harvesting in the two arms of second random-
ization (i.v. mini ICE vs non-infusional mini ICE) was
similar. The highest CD34+ yield, considering the cut-
points at 1 and 7×106/kg, as well as the total yield of
CD34+ harvested, taking the cut-points at 2 and
10×106/kg, did not appear to be predictive for the DFS
from the start of first consolidation. 
The BAVC conditioning regimen and peripheral blood
stem cell support
Autologous PBSCT was performed in 35 patients fol-
lowing the BAVC regimen. The median time from
achieving CR to time of transplant was 3.2 months
(range, 1.9–6.8 months). The median age of transplant-
ed patients was 64 years (range, 61–69 years). Patients
were grafted with a median of 10.3×108 nucleated
cells/kg (range, 0.9–20.9) containing a median of
38.3×104 CFU-GM/kg (range, 0–768.8) and 5×106 CD34+
cells/kg (range, 1.9–38.8). In one patient, the total blood
stem cell harvest remained below the target dose of
2×106/kg body weight CD34+ cells but by decision of
the physician this patient underwent PBSCT. All
patients had successful engraftment. The median time
to platelet recovery >20×109/L was 23 days (range,
14–120+ days) and that of platelet recovery >150×109/L
was 120 days (range, 21–370 days) following transplan-
tation. The median time to granulocyte recovery
>0.5×109/L was 24 days (range, 15–120+ days) and that
of granulocyte recovery >1.5×109/L was 41 days (range,
17– 120+ days) following transplantation. Severe non-
hematologic toxicities (WHO grade ≥3) included sepsis
(4 patients), pulmonary infection (2 patients), skin toxi-
city (2 patients), mucositis (1 patient), diarrhea (1
patient), nausea (1 patient), cardiac dysrhythmia (1
patient), and hypotension (1 patient).
At the time of analysis, the median follow-up from
Figure 3. Disease-free survival from complete remission achieve-
ment in patients scheduled for autologous stem cell transplanta-
tion (SCT) (61 patients). N: number of patients; O: observed num-
ber of events (relapse or death without relapse). 
Figure 4. Disease-free survival from complete remission achieve-
ment in patients from the 18 participating centers, aged less than
70 years, with a performance status <2 at the evaluation of the
first consolidation, according to treatment received: autologous
stem cell transplantation (33 patients) or a second consolidation
chemotherapy (49 patients). N: number of patients; O: observed
number of events (relapse or death without relapse). 
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transplantation was 5.0 years. Eight autografted patients
were still in continuous CR, 22 patients had relapsed (at
a median of 7 months, range: 1.7–50.6 months) and five
had died while in CR (at a median of 3.4 months, range:
2.4–24.5 months). For the 35 autografted patients, the
estimated median DFS and OS from transplantation
were 1.1 and 1.6 years, respectively. The 3-year DFS
rate was 28% (95% CI: 13 – 43%) (Figure 4) and the 3-
year OS rate was 39% (95% CI: 22–52%). The 3-year
relapse incidence was 57% (SE=9%), while the 3-year
incidence of death in CR was 15% (SE=6%). Five
patients died while in CR, two from severe infection,
two from cardiovascular dysrhythmias and one from an
unknown cause. There were no obvious differences in
DFS among patients from the 18 participating centers
receiving autologous stem cell transplant and those
receiving a second course of consolidation chemothera-
py (Figure 4).
Discussion
Preliminary reports have suggested that autologous
stem cell transplantation is feasible in elderly patients
with AML. However those reports were either from a
retrospective study19 or involved only a small number of
patients and did not give accurate information about the
potential application of the procedure in this patient
population,18 or used different conditioning regimens17
or mixed patients with different stages of disease.20 We,
therefore, addressed the question of autologous SCT in
a large, prospective, multicenter trial.
Older patients with AML are obviously more prone
than younger patients to develop complications related
to treatment. Morbidity associated with standard dose
busulfan/melphalan or cyclophosphamide/total body
irradiation bone marrow ablative conditioning regimens
resulted in inappropriate complications for elderly
patients. A pilot study has reported the follow-up of 19
elderly patients submitted to autologous stem cell trans-
plantation after idarubicin or mitoxantrone/etopo-
side/cytarabine induction and consolidation courses.17
Conditioning regimens varied and included BCNU 800
mg/m2 in six patients, busulfan 16 mg/kg in nine
patients, and BAVC in four patients. Based on this expe-
rience, BAVC was chosen as the conditioning regimen
in our study. This choice was due to the limited extra-
hematologic toxicity apart from a relevant incidence of
mucositis and severe infections during the aplastic
phase. No other extra-hematologic toxicities were doc-
umented and no significant impairment of cardiac and
respiratory function was observed after autologous
stem cell transplantation. Furthermore, hospital stay
and the kinetics of engraftment seem to be comparable
to those reported in younger patients.
We confirmed these findings in the present study, in
which only patients aged 61-70 years old, with a good
performance status after first consolidation, were
included. Sixty-one patients were considered eligible for
stem cell harvest and 57% of them mobilized a number
of CD34+ cells sufficient to perform an autotransplant.
This indicates a major selection, the transplant approach
reaching only a minority of patients. Resistant disease,
toxicity and logistic problems reduced the number of
patients to whom the transplant procedure could actu-
ally be applied. These results confirmed the inconstant
application of this post-remission strategy in elderly
patients and emphasized the overevaluation of feasibil-
ity in previous published small series.18 Toxicity after
transplantation was comparable to that observed in the
pilot study in which two patients (10%) died, and grade
2 – 4 WHO extra-hematologic toxicity was observed in
40% of cases.17 In our study all patients had successful
engraftment. However, the median platelet recovery to
>20x109/L took 120 days despite a sufficient number of
CD34+ cells having been reinfused. The number of re-
infused CD34+ cells and age at the time of transplanta-
tion has been shown to be major factors influencing
platelet engraftment.32 On an intent-to-treat analysis,
the two randomization arms, non-infusional mini ICE
and i.v. mini-ICE, provided comparable DFS and OS.26
The treatment outcome of the 61 patients who had
been scheduled for peripheral blood stem cell harvesting
in the two randomization arms was also similar. The 3-
year relapse incidence was high (69%) and median DFS
from CR was 1.12 years.
CD34+ peripheral blood cells reinfused after a mye-
loablative regimen did lead to full bone marrow recon-
stitution. There is still no agreement regarding the
X. Thomas et al.
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Table 2. Results of patients who underwent autologous stem cell
transplantation (n=35).
Features Results
Stem cell harvest
Nucleated cells/kg 10.3 (0.9–20.9)*
CFU-GM/kg 38.3 (0–768.8)*
CD34+ cells/kg 5.0 (1.9–38.8)*
Hematologic toxicity
Platelet recovery to 20×109/L 23 days (14–120+)*
Platelet recovery to 150×109/L 120 days (21–370)*
Granulocyte recovery to 0.5×109/L 24 days (15–120+)*
Granulocyte recovery to 1.5×109/L 41 days (17–120+)*
Outcome
DFS from transplantation
Median 1.1 years
3-year rate 28%
OS from transplantation
Median 1.6 years
3-year rate 39%
*median (range); DFS: disease-free survival; OS: overall survival.
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threshold dose of cells to be reinfused for consistent
peripheral blood stem cell engraftment. The thresholds
used in our study were those generally accepted by
most groups. According to these criteria, the harvest
was considered as inadequate for autografting in 20
patients. It is still uncertain whether peripheral blood as
a stem cell source carries a lower risk of tumor cell con-
tamination than does bone marrow. In a previous retro-
spective study, a higher relapse incidence was demon-
strated in patients receiving a stem cell transplant from
peripheral blood stem cells as compared to those receiv-
ing stem cell transplant from bone marrow stem cells
(63% vs 44%).19 Although it is generally assumed that
reinfusion of more than 5×106 CD34+ cells/kg is optimal,
the number of CD34+ peripheral blood stem cells is not
necessarily an accurate indicator of an adequate harvest
in AML patients. Grafts involving a high number of
CD34+ harvested peripheral blood stem cells might be
contaminated by more clonogenic malignant cells
responsible for a high relapse rate. 
The prevalence of co-morbid conditions increases
with age. Intensity of therapy is likely to exacerbate or
trigger clinical problems that may contribute to morbid-
ity and mortality during the transplantation process.
Although, recent data from patients with hematologic
malignancies suggest that a very low transplant-related
mortality can be achieved in elderly patients using
mobilized peripheral blood stem cells and conditioning
regimens without total body irradiation,33 five (14%)
transplant-related deaths were recorded in our series.
Actually, the impact on treatment outcome seen in
patients with increased comorbidity has recently been
shown to be independent of the functional status. While
not specific to elderly AML patients, comorbidity scales,
as recently suggested, may be useful to identify the
impact of comorbidities on treatment decisions.34
In the absence of new drugs or efficient modulation of
resistance, treatment of AML is based on the optimiza-
tion of delivery of currently active drugs. Our report
confirms that BAVC followed by peripheral blood stem
cell support can be safely incorporated in the therapeu-
tic strategy for AML patients over 60 years of age.
However, post-induction therapy including autologous
stem cell transplantation is only feasible in about half of
patients aged 61 to 70 years old in whom harvesting is
performed. Overall, our study demonstrates that autol-
ogous stem cell transplantation has a very minor role, if
any, as a postconsolidation approach in older patients
with AML. In our study, the long-term survival rate after
autologous stem cell transplantation was similar to
those reported in retrospective studies.21,23 Although
generating multiple biases, the comparison of patients
undergoing autologous stem cell transplantation with
those receiving the second consolidation course did not
confirm results of previous series22 and did not show
any real benefit in favor of the transplant approach in
terms of DFS. Furthermore, the outcomes described
above overestimate the true situation. The trial enrolled
patients with relatively favorable prognoses, and eligi-
bility criteria precluded the entry of patients who were
not ambulatory or who had abnormal hepatic, renal, or
cardiac function. One conclusion is that there are limita-
tions and little evidence that treatment by autologous
stem cell transplantation or other intensive treatment
modalities is improving the ultimate outcome of disease
in the elderly. Meanwhile, several new agents are
emerging that require testing, alone or in combination.
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